Clinical Trials Logo

Clinical Trial Summary

To assess the safety, tolerability and efficacy of two different doses of istaroxime, a new agent with lusitropic and inotropic activities that improves the cardiac contraction-relaxation cycle. The 2 doses of istaroxime (0.5 and 1.0 µg/kg/min) will be infused via i. v. for 24 hours in comparison with placebo, in treatment of Chinese and Italian patients with Acute Decompensated Heart Failure.


Clinical Trial Description

To assess the safety, tolerability and efficacy of two different doses of istaroxime (0.5 and 1.0 µg/kg/min) in comparison with placebo, including cardiovascular and renal tolerability, as well as changes in biological markers such as N-terminal prohormone brain natriuretic peptide (NT-proBNP) and troponin T (cTnT). The study will be conducted in 96 Chinese and Italian patients with Acute Decompensated Heart Failure. This is a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Patients were randomly assigned to one of two doses of istaroxime or placebo in a 2:1 ratio within two sequential cohorts of 60 patients each. This 31-day study includes a screening period (Days -1), a treatment period (Day 1), a post-treatment period (Days 2-4), and a follow-up period (which includes one patient visit on Day 30). In all the Italian patients and in a subset of Chinese patients pharmacokinetics and metabolism of istaroxime shall also be studied. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02617446
Study type Interventional
Source Windtree Therapeutics
Contact
Status Completed
Phase Phase 2
Start date December 2015
Completion date February 6, 2019

See also
  Status Clinical Trial Phase
Completed NCT04049045 - Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Recruiting NCT02898181 - Low Level Tragus Stimulation in Acute Decompensated Heart Failure N/A
Completed NCT02823626 - High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
Completed NCT02196038 - A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients N/A
Completed NCT02248831 - Evaluation of Cardiopulmonary Diseases by Ultrasound N/A
Completed NCT00693745 - Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF N/A
Not yet recruiting NCT04391231 - HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial Phase 4
Recruiting NCT05206422 - DORAYA-HF Early Feasibility Study N/A
Recruiting NCT01960218 - Gas Exchange for Predicting Hospital Heart Failure Readmissions N/A
Terminated NCT00904488 - Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure Phase 4
Terminated NCT02620384 - Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study. Phase 3
Completed NCT04318093 - Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure Phase 2
Recruiting NCT06161649 - Mobile Education System to Improve Disease Knowledge, Self-efficacy and Quality of Life in Patients With Heart Failure N/A
Completed NCT02289508 - Role of USCOM in Adult Patients With Heart Failure N/A
Terminated NCT01457053 - Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics N/A
Completed NCT04877652 - DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
Completed NCT03505788 - Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) Phase 4
Completed NCT03146754 - A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE) N/A
Not yet recruiting NCT06414759 - Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload Phase 4